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University of Central Florida College of Medicine, Orlando, FloridaBACKGROUND & AIMS: Based on histologic features, variants in STAT6 are associated with a poor initial response to
proton pump inhibitor (PPI) therapy in pediatric patients with eosinophilic esophagitis (EoE).
We investigated whether these genetic variants are associated with a poor long-term response
in children with EoE who initially responded to PPI therapy.METHODS: We performed a prospective longitudinal cohort study of children ages 2 to 16 years who met
the diagnostic criteria for EoE (‡15 eosinophils/high-power field [eos/hpf]), responded to 8
weeks of treatment with 2 mg/kg/d PPI (<15 eos/hpf), and whose dose then was reduced to 1
mg/kg/d PPI (maintenance therapy) for 1 year, at which point biopsy specimens were collected
by endoscopy. Genomic DNA was isolated from formalin-fixed paraffin-embedded biopsy tissue
and was genotyped for variants of STAT6. Remission of inflammation was assessed at eos/hpf
thresholds of <15 and £5.RESULTS: Among 73 patients who received 1 mg/kg/d PPI maintenance therapy for 1 year, 13 patients
(18%) had 6 to 14 eos/hpf, 36 patients (49%) had 5 or fewer eos/hpf, and 24 patients (33%)
relapsed to EoE (‡15 eos/hpf). Carriage of any of 3 STAT6 variants in linkage disequilibrium (r2
‡0.8; rs324011, rs167769, or rs12368672) was associated with a 2.3- to 2.8-fold increase in the
odds of EoE relapse, and with a 2.8- to 4.1-fold increase in the odds of having 6 to 14 eos/hpf.
For rs324011, the odds ratio [95% CI] for relapse was 2.77 [1.11, 6.92]; P [ .029, and the odds
ratio [95% CI] for having 6 to 14 eos/hpf was 3.06 [1.27, 7.36]; P [ .012.CONCLUSIONS: Pediatric EoE patients who initially respond to PPI therapy and carry STAT6 variants rs324011,
rs167769, or rs12368672 are at increased risk of relapse after 1 year of PPI maintenance therapy.Keywords: Esophagus; Biomarker; Response to Treatment; Immune Response.Abbreviations used in this paper: BLRM, binary logistic regression
modeling; EoE, eosinophilic esophagitis; eos/hpf, eosinophils per high-
power microscope field; EREFS, Eosinophilic Esophagitis Endoscopic
Reference Score; mRNA, messenger RNA; OR, odds ratio; PPI, proton
pump inhibitor; PPI-REE, proton pump inhibitor responsive eosinophilic
esophagitis; RR, rate ratio; SNP, single-nucleotide polymorphism.
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https://doi.org/10.1016/j.cgh.2020.08.020Recent changes to the eosinophilic esophagitis(EoE) clinical consensus guidelines now support
proton pump inhibitor (PPI) medications as a primary
therapy for both pediatric and adult EoE.1 Gutierrez-
Junquera et al.2 previously reported a PPI response
rate of 68.6% (PPI–responsive esophageal eosinophilia
[PPI-REE], <15 eosinophils/high-power field [eos/hpf])
after 8 weeks of high-dose PPI therapy (twice daily, 1
mg/kg/dose; maximum, 80 mg/d) in children presenting
with 15 or more eos/hpf and meeting the diagnostic
criteria for EoE. Of the initial responders, it subsequently
What You Need to Know
Background
More than 30% of pediatric patients who are
receiving long-term proton pump inhibitor (PPI)
maintenance therapy for eosinophilic esophagitis
(EoE) relapse. It is not currently possible to identify
which patients will relapse.
Findings
Pediatric EoE patients with an initial response to PPI
therapy and who carry STAT6 variants rs324011,
rs167769, or rs12368672 are at increased risk of
relapse after 1 year of PPI maintenance therapy.
Implications for patient care
Pediatric patients with EoE should be tested for
variants in STAT6 that are associated with a poor
response to long-term PPI maintenance therapy.
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after 1 year of low-dose PPI maintenance therapy (once
daily, 1 mg/kg/d; maximum, 40 mg/d). Although PPI
therapy is effective in treating inflammation associated
with EoE, data on the safety of double-dose and long-
term PPI treatment in children are scarce.4 Reports
have indicated multiple potential associations between
PPI use and comorbidities in children,5 including an
increased risk of respiratory tract6 or gastrointestinal in-
fections7 arising from ingestion of orally acquired patho-
gens that otherwise would be rendered harmless by
gastric acid.8–10 Therefore, among children with EoE, it
is important clinically to identify not only the minimal
effective PPI dose and duration for a child, but also to
identify children who will benefit from low-dose PPI
maintenance therapy without the additional risk
incurred from endoscopic procedures that will be
required if they were to relapse.
Esophageal eosinophilia in EoE is driven by STAT6-
dependent local expression of eotaxin-3 (CCL26), and
PPIs can block the chromatin remodeling that is neces-
sary for STAT6 binding and transcriptional activation of
CCL26.11 Individual variability in PPI pharmacokinetics
and pharmacodynamics is influenced strongly by genetic
variation in CYP2C19.12,13 We have shown previously
that carriers of STAT6 genetic variant rs324011 are 6.1-
fold more likely to fail to achieve complete resolution of
inflammation than noncarriers and that this effect is
compounded in carriers of the CYP2C19*17 increased
function variant.14 Genetic variants that are associated
with response to long-term PPI maintenance therapy for
pediatric EoE remain to be characterized. We hypothe-
sized that genetic variants of STAT6 and CYP2C19 may
influence long-term response to PPI therapy in children
with EoE.Methods
Study Participants
Study participants were recruited prospectively to
the parent study at 2 pediatric hospitals in Madrid, Spain,
between February 2013 and December 2017, as previ-
ously described.2,3 Briefly, children from 2 to 16 years of
age who were referred to the pediatric gastroenterology
unit with at least 1 symptom possibly related to esoph-
ageal dysfunction including heartburn, chest pain, food
impaction, abdominal pain, vomiting, regurgitation,
dysphagia, and feeding difficulties, in addition to the
finding of esophageal eosinophilia (peak value, 15 eos/
0.24 mm2), were enrolled in the primary study. The
study was conducted according to the Declaration of
Helsinki. All patients or parents provided their consent
to participate in the study. Approvals from the Ethics
Committee at the Hospital Universitario Puerta de
Hierro-Majadahonda and the Hospital Universitario
Severo Ochoa were obtained. Because CYP2C19 is notexpressed in the human liver during infancy,15 only
children ages 2 years or older were included in the
present study. After an initial endoscopy with biopsy,
participants were treated with PPI (n ¼ 103 esomepra-
zole, n ¼ 3 lansoprazole, n ¼ 3 omeprazole; twice daily at
a target dose of 1 mg/kg/dose, for a total dose of 2 mg/
kg/d, up to a maximum dose of 80 mg/d), for 8 weeks
(high-dose). Then, a second endoscopy with biopsy was
performed while participants still were taking PPI.
Seventy-three responders (<15 peak eos/0.24 mm2)
were stepped down to once-daily dosing of 1 mg/kg/
d PPI for 1 year (low-dose), at which time a third
endoscopy with biopsy was performed. Patient outcomes
at the end of the maintenance period have been reported
previously.3 As reflected in Supplementary Figure 1, the
dose range across all 73 participants was 0.23 to 1.22
mg/kg/d. One patient received less than 0.5 mg/kg/d.
The variation in PPI dose (mg/kg/d) was the result of
either reaching the maximum daily dose of 40 mg, or a
result of trying to achieve their target dose while being
restricted to prescribing available esomeprazole tablet
preparations of 20 and 40 mg. Additional details about
the current cohort can be found in the Supplementary
Methods section.
Histologic Definition of Disease and Response
to Proton Pump Inhibitor
Biopsies were performed (at least 2 from the distal
esophagus and 2 from the proximal-mid-esophagus) ac-
cording to the guidelines for diagnosis and monitoring of
EoE.1,16 All biopsies were targeted to areas with
abnormal endoscopic findings, if present. After fixation in
10% buffered formalin and staining with H&E, eosinophil
counts from single high-power microscope fields corre-
sponding to an area of 0.24 mm2 were recorded.
Esophageal eosinophilia was defined as having a peak
Table 1. Patient Characteristics
<15 eos/hpf (n ¼ 49)a 15 eos/hpf (n ¼ 24)a P valueb
Therapy
Esomeprazole 45 (91.8) 23 (96) 1
PPI maintenance dose, mg/kg/d 0.93 (0.6) 0.91 (0.65) .62
Characteristics at diagnosis
Caucasian 48 (98) 23 (95.8) 1
Male 34 (69.4) 20 (83.3) .26
Age at diagnosis, y 10.37 (5.46) 9.58 (6.43) .41
Height (z-score) -0.51 (2.53) -0.32 (2.82) .46
Weight (z-score) -0.54 (1.58) -0.43 (1.6) .62
History at diagnosis
Allergic rhinitis 22 (44.9) 8 (34.8) .45
Asthma 17 (34.7) 13 (54.2) .13
Atopy 10 (20.4) 6 (25) .77
Food allergies 10 (20.4) 10 (41.7) .09
Symptoms at diagnosis
Abdominal pain 35 (71.4) 14 (58.3) .30
Dysphagia 18 (36.7) 12 (50) .32
Food refusal 14 (28.6) 7 (29.2) 1
Heartburn 15 (30.6) 5 (20.8) .42
Impaction 10 (20.4) 9 (37.5) .16
Regurgitation/vomiting 13 (26.5) 7 (29.2) 1
Retrosternal pain 11 (22.4) 4 (16.7) .76
EREFS
EREFS at diagnosis 4 [3–4] 4 [3–4] .49
Edema at the beginning of the maintenance period 0 [0–1] 1 [1–1] .001
Furrows at the beginning of the maintenance period 0 [0–0] 0 [0–1] .07
EREFS at the beginning of the maintenance period 1 [1–2] 2 [2–3] <.001
Endoscopy
PPI-REE, <15 and >5 eos/hpf, end of high-dose period 16 (32.7) 13 (54.2) .13
PPI-REE, 5 eos/hpf, end of high-dose period 33 (67.3) 11 (22.4) .13
Peak eos/hpf at diagnosis 46 [35–72] 55 [30–80] .64
Delta peak eos/hpf over the high-dose period -44 [-70 to -36] -50 [-77 to -25] .84
Peak eos/hpf at end of high-dose period 2 [0–3] 7 [0–9] .15
eos/hpf, eosinophils per high-powered microscope field; EREFS, Eosinophilic Esophagitis Endoscopic Reference Score; PPI-REE, proton pump inhibitor
responsive eosinophilic esophagitis.
aParticipant counts are reported as n (%N); a Box Cox transformation is applied to continuous data and the back transformed means (SD) are reported; count data
(other than participant count) is reported as median [95% CI].
bReported value is for the Fisher exact test, 2-sided (participant counts), the Welch t test, 2-sided (continuous data), or negative binomial regression (count data).
Values in bold font indicate characteristicts that are significantly different between groups. No correction has been made for multiple testing.
- 2020 STAT6 Variants and PPI Therapy for EoE 3eosinophil count of 15 or more per high-power field in 1
or more esophageal biopsy specimens at baseline. After 8
weeks of high-dose PPI therapy, response was defined as
fewer than 15 eos/hpf on all esophageal biopsy speci-
mens obtained during the follow-up upper gastrointes-
tinal endoscopy. After 1 year of PPI maintenance therapy,
response was assessed at thresholds of <15 eos/hpf and
5 eos/hpf.
Genotyping
Genomic DNA was isolated from formalin-fixed
paraffin-embedded sections of esophageal biopsy tis-
sue,17 and genotyping reactions were conducted as pre-
viously described.17 The CYP2C19 single-nucleotide
polymorphisms (SNPs) investigated and assays used
were as previously described.14,17 The STAT6 SNPsinvestigated and the TaqMan assays used (Applied Bio-
systems, Waltham, MA) were as follows: rs1059513
(C___7480847_10), rs324011 (C____620399_10),
rs167769 (C____620401_20), and rs12368672
(C__31186828_10). Genotype counts, SNP frequencies,
and Hardy–Weinberg equilibrium P values are shown in
Supplementary Table 1. SNPs rs324011, rs167769, and
rs12368672 were in linkage disequilibrium (r2, >0.8)
both in our population and in the 1000 Genomes phase 3
data set.18Statistical Analysis
Analyses were conducted in R base versions 3.5.1
(2018)19 and are described in the Supplementary
Materials. Inflation of type 1 error through multiple
Figure 1. Distribution of eosinophil counts at the initiation of maintenance therapy and the change in peak eosinophil counts
during maintenance therapy differ by STAT6 genotype. Violin plots of (A) peak eosinophil count at the end of the 1-year proton
pump inhibitor (PPI) maintenance period or (B) peak eosinophil count change (end minus beginning) during the 1-year
maintenance period, stratified by STAT6 genotype (dominant genetic model). Black points indicate eos counts for in-
dividuals and have been jittered on the x-axis to reduce overlap. Black lines within shaded regions indicate (from the bottom)
first, second, and third quantiles based on the density distribution. Horizontal brackets with asterisks indicate that the dis-
tributions are significantly different (P  .05).
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values using the Bonferroni method.20
Results
The consort diagram for this study is shown in
Supplementary Figure 1. The baseline characteristics of
study patients stratified by clinical outcome are detailed
in Table 1. Overall, the PPI dose for maintenance therapy
ranged from 0.23 to 1.22 mg/kg/d, and 67% of partici-
pants scored fewer than 15 eos/hpf at their 1 yearfollow-up evaluation. Responders (<15 eos/hpf) and
nonresponders (15 eos/hpf) received similar mean PPI
doses. Patients whose inflammation eventually would
relapse while on maintenance therapy had a higher
median Eosinophilic Esophagitis Endoscopic Reference
Score (EREFS)21 after completion of the initial 8 weeks of
high-dose PPI therapy (15 eos/hpf, median EREFS
[95% CI], 2 [2,3] vs <15 eos/hpf, 1 [1,2]; P <.001),
driven primarily by increased edema (15 eos/hpf: odds
ratio [OR] [95% CI], 10.2 [2.53, 41.16]; P ¼ .001) and
furrows (15 eos/hpf: OR [95% CI], 3.53 [0.92, 13.51];
- 2020 STAT6 Variants and PPI Therapy for EoE 5P ¼ .065), in patients who eventually would relapse.
Binary logistic regression modeling (BLRM) with race,
sex, age, PPI dose, and PPI type as covariates found that
EREFS at this point, predicted histologic relapse of
inflammation after 1 year of maintenance therapy (15
eos/hpf: OR [95% CI], 3.70 [1.64, 8.37]; P ¼ .002),
meaning that for every 1-point increase in EREFS, pa-
tients were 3.7 times more likely to experience histologic
relapse. EREFS at the beginning of the high-dose PPI
therapy period did not predict response to maintenance
therapy. From BLRM, we found that patients who scored
5 or fewer eos/hpf after the initial 8 weeks of high-dose
PPI therapy were greater than 3-fold more likely to
remain in remission during maintenance therapy than
individuals who initially scored fewer than 15 (<15 eos/
hpf: OR [95% CI], 3.06 [1.04, 9.01]; P ¼ .042) and were
4.5-fold more likely to remain at 5 or fewer eos/hpf after
1 year of maintenance therapy (5 eos/hpf: OR [95%
CI], 4.51 [1.54, 13.15]; P ¼ .006).
We previously reported that carriage of STAT6 vari-
ants rs324011, rs167769 and rs12368672 was associ-
ated with an increased eosinophil count in the distal
esophagus, relative to noncarriers, on biopsy samples
obtained before initiating PPI therapy,14 while carriage
of STAT6 variant rs1059513 was associated with
decreased eosinophil counts in the distal esophagus.
Therefore, we analyzed this group of SNPs for associa-
tion with outcome of PPI maintenance therapy. Genotype
counts, SNP frequencies, and Hardy–Weinberg equilib-
rium P values for the variants examined in the study
population are shown in Supplementary Table 1.
The distributions of both peak esophageal eosinophil
counts at the end of 1 year of maintenance therapy over
all regions sampled (distal and medium proximal) and
the change in peak eosinophil counts over the mainte-














dom, dominant genetic model; eos/hpf, eosinophils per high-powered field; PPI,
aPeak value was the highest recorded value from all biopsy specimens in all regi
bGenetic model coding, dominant: carriage of 0 copies of the SNP is coded as 0
cReported value is from negative binomial regression modeling with eosinophil
variable, adjusted for race, age, sex, PPI dose (mg/kg/d), and type of PPI.noncarriers and carriers of rs324011, rs167769, and
rs12368672 (Figure 1A and B, respectively). In partic-
ular, the quantiles of eosinophil count distribution den-
sity for both metrics were skewed to larger values in
carriers relative to noncarriers. By using negative bino-
mial regression (dominant model, covariates as
described earlier), we found that carriage of rs324011,
rs167769, and rs12368672 tended to be associated with
a 2.60- to 3.12-fold increase in median peak esophageal
eosinophil count at the end of 1 year of maintenance
therapy relative to noncarriers (Table 2)
(rs324011, median change in peak eos/hpf [95% CI], þ9
[-2,20] eos/hpf; rate ratio (RR) [95% CI], 3.12
[1.25, 7.76]; P ¼ .028). The same group of SNPs also
tended to be associated with a 1.49- to 1.60-fold increase
in change in peak eosinophil counts over the 1-year
maintenance period (Table 2) (rs324011, median
change in peak eos/hpf [95% CI], þ4 [0,17] eos/hpf; RR
[95% CI], 1.60 [1.12, 2.30]; P ¼ .022). Although in-
dividuals who carry rs1059513 had lower peak eosino-
phil counts at the end of 1 year of maintenance therapy
than noncarriers (median change in peak eos/hpf [95%
CI], -5 [-19,9]), the result was not significant in this
population.
Finally, we tested for associations between carriage of
STAT6 and/or CYP2C19*17 variants and outcome of PPI
maintenance therapy (Figure 2). In BLRM, examining the
association between STAT6 variant and scoring 15 or
more eos/hpf after 1 year of maintenance therapy (ad-
ditive genetic model, covariates as described earlier),
individuals who were carriers of rs324011, rs167769,
and rs12368672 had a 2.32- to 2.80-fold increased odds
of scoring 15 or more eos/hpf after 1 year of PPI
maintenance therapy than noncarriers (rs324011, 15
eos/hpf OR [95% CI], 2.77 [1.11, 6.92]; P ¼ .029). When
considering individuals who experienced some level ofarriage of STAT6 Variants
f, dom ¼ 0,
n [95% CI]
eos/hpf, dom ¼ 1,
median [95% CI] RR [95%CI] P valuec
[1–10] 3 [0–26] 0.71 [0.25–2.05] 1
0 [0–9] 9 [3–20] 3.12 [1.25–7.76] .028
0 [0–9] 9 [3–17] 2.73 [1.10–6.74] .060
.5 [0–4] 10 [3–20] 2.60 [1.04–6.50] .082
0 [0–6] 2 [0–26] 0.96 [0.63–1.46] 1
[-1 to 0] 4 [0–17] 1.60 [1.12–2.30] .022
[-1 to 0] 4 [0–12] 1.55 [1.08–2.22] .032
[-1 to 1] 4 [0–17] 1.49 [1.03–2.14] .064
proton pump inhibitor; RR, rate ratio; SNP, single-nucleotide polymorphism.
ons sampled.
, carriage of 1 or 2 copies of the SNP is coded as 1.
counts as the dependent variable and genotype counts as the independent
Figure 2. Histologic relapse of eosinophilic esophagitis (EoE) after 1 year of proton pump inhibitor (PPI) maintenance therapy
was associated with carriage of STAT6 variants. Binary logistic regression modeling (BLRM) of STAT6 variants as predictors of
histologic relapse (15 eosinophils [eos]/0.24 mm2, top) or (>5 eos/0.24 mm2, middle), over the 1-year maintenance therapy
period and over both the initial 8-week, high-dose therapy and 1-year maintenance therapy periods combined (15 eos/0.24
mm2, bottom). The odds of failing to respond to therapy (15 eos/0.24 mm2) increase toward the right. All models include race,
sex, age, PPI dose, and PPI type as covariates. hpf, high-powered field.
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than complete remission (<15 and >5 eos/hpf) after 1
year of maintenance therapy, carriage of rs324011,
rs167769 and rs12368672 increased the OR 2.78- to
4.11-fold (rs324011: <15 and >5 eos/hpf OR [95% CI],
3.06 [1.27, 7.36; P ¼ .012). When considering both
therapy periods together (8 weeks þ maintenance), in-
dividuals who carry rs324011, rs167769 and
rs12368672 have a 2.6- to 2.8-fold increased odds of
failing PPI therapy at some point (rs324011: 15 eos/
hpf OR [95% CI], 2.77 [1.17, 6.57; P ¼ .020). Interest-
ingly, we did not find significant associations between
carriage of CYP2C19*17 and outcome of PPI maintenance
therapy, and we did not see interactions between
rs324011, rs167769, rs12368672 and CYP2C19*17 in
this population.Discussion
In this study, we identify novel associations between
common genetic variants in STAT6 and histologic relapse
of eosinophilic inflammation in pediatric patients who
are receiving 1 mg/kg/d PPI therapy for long-termmaintenance of inflammation remission. Specifically,
carriage of any 1 of 3 STAT6 variants in linkage
disequilibrium (rs324011, rs167769, or rs12368672) is
associated with a 2.60- to 3.12-fold increase in peak
eosinophil count at the end of 1 year of maintenance
therapy; a 1.49- to 1.60-fold increase in the difference
between peak eosinophil counts at the end and at the
beginning of 1 year of maintenance therapy; and a 2.32-
to 2.80-fold increase in the odds of histologic relapse to
EoE (15 eos/hpf) during the maintenance period. This
is consistent with our previous findings after 8 weeks of
high-dose PPI therapy that carriage of the same group of
STAT6 variants was associated with a 6.1-fold increased
odds of failing to achieve complete PPI-REE14 (5 eos/
hpf). The study found an association between STAT6
variants and response to long-term PPI maintenance
therapy for EoE and may have implications for clinical
management.
In contrast to our previous findings in the initial 8-
week, high-dose PPI study that showed the influence of
CYP2C19*17 within the interquartile range of all PPI
dosages given and an interaction between CYP2C19*17
and STAT6 rs324011, we saw neither association in the
current study. This finding also was contrary to a report
- 2020 STAT6 Variants and PPI Therapy for EoE 7by Molina-Infante et al,22 suggesting that CYP2C19*17
predicted failure of long-term PPI maintenance therapy
(predominantly omeprazole) in an adult retrospective
cohort study. It is possible that the predominant PPI type
(eg, omeprazole) and dose combinations used by Molina-
Infante et al22 were more sensitive to the effects of
CYP2C19*17 than those used in our studies.2,3 This
interpretation is strengthened by evidence-based guide-
lines published by the Dutch Pharmacogenetics Working
Group,23 which recommend increasing the dose of
omeprazole, lansoprazole, and pantoprazole by 3-, 4-,
and 5-fold, respectively, in carriers of CYP2C19*17 to
maintain therapeutic efficacy for acid suppression, while
refraining from making a similar recommendation for
esomeprazole. This is consistent with estimated relative
potencies of 0.23, 0.9, and 1.6 for pantoprazole, lanso-
prazole, and esomeprazole in general, compared with
omeprazole, based on mean 24-hour gastric pH mea-
surements.24 Although there is limited evidence to sup-
port a role for gastric acid suppression in the mechanism
of PPI-REE, PPI dose dependency has been established
for the anti-inflammatory mechanism through which PPI
may be functioning in EoE.11 Because the majority of
patients in our studies receive esomeprazole and given
that the AUC of esomeprazole is almost 2-fold greater
than an equivalent dose of omeprazole,25 we would
expect to see decreased influence of CYP2C19*17 in our
studies relative to studies that predominately use
omeprazole, lansoprazole, or pantoprazole. Conse-
quently, we suspect that the current work is under-
powered to see the influence of CYP2C19*17 or its
interaction with rs324011.
The association we characterize between STAT6 var-
iants and response to PPI therapy for long-term main-
tenance of inflammation remission for EoE is consistent
with the known role of STAT6 as a critical mediator of
the interleukin 4 and interleukin 13 cytokine signaling
pathways. Rs324011 is located in intron 2 of the STAT6
gene. In vitro studies have suggested that the major allele
variant of rs324011 (C) is associated with transcriptional
silencing of STAT6, while the minor allele variant (T)
creates a functional nuclear factor-kB binding site that is
associated with both enhanced STAT6 pre–messenger
RNA (mRNA) expression and increased aberrant
splicing through intron retention.26 Analysis of gene
expression quantitative trait loci in B cells and mono-
cytes shows that rs324011 (T) dose-dependently is
associated with increased STAT6 mRNA expression
when using a probe that tags the 3’ untranslated re-
gion.27 Genotype tissue expression28 analysis identifies
rs324011 (T) as a significant STAT6 pre-mRNA splicing
quantitative trait loci that is associated with aberrant
splicing through intron retention in a tissue-dependent
manner. Interestingly, esophageal mucosa is among the
tissues in which aberrant splicing of STAT6 pre-mRNA is
greatest. Exactly how the diverse biological phenotypes
associated with rs324011, or other genetic variants in
linkage disequilibrium with rs324011, interact toincrease esophageal eosinophil counts in carriers of
rs324011 remains to be determined.
This study had several limitations including small
sample size, variation in PPI dose, length of therapy,
and the potential for additional genetic variants
identified in previous genome-wide association
studies29,30 to act as confounders and influence his-
tologic outcome of PPI therapy. Because of minor
heterogeneity in race (72 European Caucasians, 1 Af-
rican American, and 1 Arab) and type of PPI (68 eso-
meprazole, 3 omeprazole, and 2 lansoprazole),
corrections for these covariates were included in our
regression analyses.
Conclusions
Carriage of STAT6 variants rs324011, rs167769 or
rs12368672 increase the odds that pediatric patients
will fail PPI therapy for EoE at some point during either
the initial 8-week, high-dose therapy or during the sub-
sequent 1 year of low-dose maintenance therapy. Large
prospective clinical studies are needed to fully charac-
terize which factors contribute to PPI response vari-
ability (20%–70%4) including PPI type, PPI dose, and
individual genetics. EoE patients may benefit from
personalized, genotype-guided therapy selection, and/or
dose optimization.
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Relationship of the Current Cohort to Those of
Our Earlier Studies
In the initial study (C. Gutierrez-Junquera, S. Fer-
nandez-Fernandez, M.L. Cilleruelo, et al., High preva-
lence of response to proton-pump inhibitor treatment
in children with esophageal eosinophilia, J Pediatr
Gastroenterol Nutr 62, 2016, 704–710.), 56 patients
were recruited between February 2013 and April 2015,
5 of whom subsequently were excluded (51 patients
met inclusion criteria). These patients received 2 mg/
kg/d PPI therapy for 8 weeks (induction phase). Be-
tween May 2015 and August 2017, an additional 58
patients completed the induction phase and were
added to the initial group of 51 patients for a total of
109 patients. Of these 109 patients, 72 achieved his-
tologic remission after the induction phase and were
stepped-down to 1 mg/kg/d PPI therapy for 12 months
(maintenance phase). Of these 72 patients, 2 were lost
to follow-up evaluation, 1 refused a follow-up endos-
copy, and 12 had their follow-up visits before
completing 12 months of maintenance therapy. The
remaining 57 patients were the subject of the second
study (C. Gutierrez-Junquera, S. Fernandez-Fernandez,
M.L. Cilleruelo, et al., Long-term treatment with proton
pump inhibitors is effective in children with eosino-
philic esophagitis, J Pediatr Gastroenterol Nutr 67,
2018, 210–216.). In our third study (E.B. Mougey, A.
Williams, A.J.K. Coyne, et al., CYP2C19 and STAT6 var-
iants influence the outcome of proton pump inhibitor
therapy in pediatric eosinophilic esophagitis, J Pediatr
Gastroenterol Nutr 69, 2019, 581–587. 92 partici-
pants), we examined the 57 induction phase re-
sponders from our second study together with the 37
nonresponders, 2 of whom were excluded because they
received swallowed steroids in addition to PPIs. In the
present study, the 57 participants of the second study
were combined with an additional 17 patients who
completed the maintenance phase between September
2017 and February 2019, for a total of 73 participants.Statistical Methods
Analyses were conducted in R base versions 3.5.1
(2018).1 Continuous variables were transformed using the
powerTransform function of the R package car.2 The sta-
tistical test used was dependent on the data distribution. A
2-sided Fisher exact test (exact P value) was used for
comparison of proportions in count data. A 2-sided Wil-
coxon rank-sum test (exact P value) was used to determine
whether 2 independent samples were selected from pop-
ulations having the same distribution. Negative binomial
regression from the R statistical package MASS,3 was used
with auto-optimization of the dispersion parameter to
assess relationships between independent variables and
count-dependent variables. Binary logistic regression was
used to assess relationships between independent vari-
ables and binary-dependent variables. Plots were pro-
duced using the function ggplot from the R statistical
package ggplot2.4 Forest plots were prepared with the R
package forestplot.5 When differences between values
with CIs were calculated, the MOVER-D method6 was used
to propagate imprecision. Inflation of type 1 error through
multiple testing has been addressed by correction of re-
ported P values using the method of Bonferroni.7Supplementary References
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Supplementary Figure 1. Consort diagram. Endoscopy #1
was performed for an initial diagnosis. Endoscopy #2 was
performed after the initial 8-week, high-dose therapy period.
Endoscopy #3 was performed at the end of the 1-year
maintenance period. Proton pump inhibitor (PPI) dosages
were as follows: during the initial 8 weeks, patients received
two 1 mg/kg PPI doses per day, up to a maximum of 80 mg/
d; for 1-year maintenance therapy, patients received one 1
mg/kg PPI dose per day, up to a maximum of 40 mg/d. Pa-
tient counts and percentages of the total count are reported
as follows: n ¼ xx; N%. eos, eosinophils; hpf, high-powered
field (0.24 mm2); PPI-REE, PPI-responsive eosinophilic
esophagitis; yo, years old.
Supplementary Table 1. SNPs, Minor Allele Frequency, and Hardy–Weinberg Equilibrium
SNP Position MAF HWE
<15 eos/hpf 15 eos/hpf
P valuean, MM/mM/mm n, MM/mM/mm
CYP2C19*2 rs4244285 chr10:94781609 0.199 0.721 35/14/0 11/11/2 .022
CYP2C19*17 rs12248560 chr10:94761650 0.171 1 34/13/2 16/8/0 .716
STAT6 rs1059513 chr12:57095676 0.130 1 37/11/1 18/6/0 1
STAT6 rs324011 chr12:57108149 0.377 0.321 21/24/4 5/15/4 .162
STAT6 rs167769 chr12:57109742 0.363 0.612 22/23/4 6/14/4 .214
STAT6 rs12368672 chr12:57118437 0.390 0.805 21/24/4 5/13/6 .074
NOTE. Variants in bold are in linkage disequilibrium (r2  0.8).
chr, chromosome; eos/hpf, eosinophils per high-power field; HWE, Hardy–Weinberg equilibrium; MAF, minor allele frequency; MM, major allele homozygote; mM,
minor allele heterozygote; mm, minor allele homozygote; SNP, single-nucleotide polymorphism.
aThe reported P value is for the Fisher exact test, 2-sided, without correction for multiple testing.
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